Teva's IL-15 antibody nears celiac Phase 2a readout with enrollment complete
TEV-53408 finished enrollment at 50 patients and Teva has guided to H2 2026 topline data testing whether blocking IL-15 can reverse villous atrophy in celiac disease.
Executive Summary
- Teva has completed enrollment in a placebo-controlled Phase 2a trial testing whether blocking a specific immune signal can reverse intestinal damage in celiac disease, with topline results guided for the second half of 2026.
- Celiac disease has no approved drug therapy, and a positive result would mark an early test of an immune-signaling mechanism that no other program in the field is pursuing.
- The trial has moved through its stages without disruption: enrollment reached target, recruitment closed, and the sponsor's own guidance has narrowed rather than widened as the readout approaches.
- Several sponsors are testing distinct mechanisms in celiac disease, but none shares TEV-53408's approach, leaving this readout as an isolated test of its own hypothesis rather than one measured against a direct rival.
The catalyst
Teva Pharmaceuticals said in a March 2026 disclosure that it expects topline results from its Phase 2a trial of TEV-53408 in celiac disease during the second half of 2026, updating an earlier guidance statement that had simply pointed to sometime in 2026. The trial, registered as NCT06807463, is testing TEV-53408 against placebo in adults with biopsy-confirmed celiac disease who have followed a gluten-free diet for at least 12 months but continue to show intestinal damage. The primary endpoint is the change from baseline in villous atrophy, measured by the villous height-to-crypt depth ratio, a histological marker of intestinal healing, alongside four safety measures covering treatment-emergent adverse events and study discontinuations. OmniAb+1OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMar 4, 2026A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseNCT06807463
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where the trial stands
The study started dosing in March 2025 and completed enrollment at its target of 50 patients across sites in the United States, Australia and Finland. It moved to Active, not recruiting status in April 2026, and its primary completion date is September 15, 2026, one month later than the August 2026 date originally registered. Enrollment grew from an initial target of 40 to 48 patients in May 2025, then to 50 at the close of recruitment, changes that sit within the routine range the trial's own operational tracking flags only above a 20% swing. Neither move altered the primary endpoints or the analysis population. NCT06807463A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseNCT06807463
The regulatory backdrop
The FDA granted TEV-53408 Fast Track designation for celiac disease in May 2025, a status that allows more frequent agency interaction during development but does not itself signal an efficacy outcome. Celiac disease currently has no FDA-approved pharmacologic treatment; the gluten-free diet remains the standard of care, and a share of patients continue to show persistent intestinal injury despite adherence, which is the population this trial is designed to test. OmniAbOmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMar 4, 2026
The competitive field
Celiac disease drug development is active but mechanistically scattered. Programs in clinical testing include Dr. Falk Pharma's ZED1227, a small-molecule transglutaminase-2 inhibitor; Sanofi's amlitelimab, an anti-OX40L antibody; Forte Biosciences' FB102; and Chugai's DONQ52, alongside Takeda's gluten-specific T-cell therapy TAK-101 and Massachusetts General Hospital's ritlecitinib, a JAK3 inhibitor. None of these programs targets the same pathway as TEV-53408, so the readout has no direct mechanistic comparator within the current field; the nearest points of reference are Sanofi's amlitelimab trial, which is nearing its own completion in August 2026, and Chugai's DONQ52 study, both of which share only the indication. With no pharmacologic therapy validated in this setting, a reduction in villous atrophy that separates from placebo, paired with a clean safety profile, would be the result that establishes TEV-53408's mechanism as a viable path forward.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.